Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Sees Large Decline in Short Interest

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) saw a large drop in short interest in September. As of September 15th, there was short interest totaling 6,607 shares, a drop of 50.9% from the August 31st total of 13,469 shares. Based on an average daily volume of 43,279 shares, the short-interest ratio is currently 0.2 days. Currently, 0.6% of the shares of the stock are sold short.

Regentis Biomaterials Stock Down 2.1%

Shares of NYSEAMERICAN RGNT traded down $0.04 during midday trading on Tuesday, reaching $1.85. The company’s stock had a trading volume of 58,605 shares, compared to its average volume of 1,869,644. The company has a 50 day moving average price of $1.97 and a 200 day moving average price of $2.63. Regentis Biomaterials has a one year low of $1.23 and a one year high of $15.50.

Regentis Biomaterials (NYSEAMERICAN:RGNT) last posted its quarterly earnings results on Friday, September 11th. The company reported ($0.22) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Regentis Biomaterials

An institutional investor recently bought a new position in Regentis Biomaterials stock. AIGH Capital Management LLC acquired a new stake in shares of Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned approximately 5.79% of Regentis Biomaterials at the end of the most recent quarter.

Regentis Biomaterials Company Profile

Regentis Biomaterials Ltd. is an Israel-based medical device company developing biomaterial technologies for the treatment of cartilage injuries and other orthopedic conditions. The company focuses on regenerative solutions intended to support the repair of damaged tissue while reducing the need for more invasive procedures.

Its lead product is GelrinC, a synthetic, cell-free hydrogel implant designed for the treatment of focal cartilage defects in the knee. The product is placed arthroscopically and forms a scaffold intended to integrate with surrounding tissue and support the regeneration of hyaline-like cartilage.

Regentis Biomaterials operates as a clinical-stage company, with activities centered on product development, clinical evaluation, regulatory advancement and potential commercialization of its orthopedic biomaterial platform.